β-Catenin Expression Correlates With Prognosis in Hepatocellular Carcinoma Patients Treated With Transcatheter Arterial Chemoembolization.
Transcatheter arterial chemoembolization (TACE) is one of the most widely used palliative therapies for the unresectable hepatocellular carcinoma (HCC). However, a large difference is found in prognosis among patients treated with TACE. The aim of the present study was to investigate the prognostic value of β-catenin in HCC patients treated with TACE. Seventy patients with HCC were included in this study. Expression of β-catenin was determined by immunohistochemistry in biopsy samples taken before TACE. The patients were treated with TACE and followed-up. Clinicopathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated to analyze the association of β-catenin expression with prognosis for HCC patients after TACE. HCC patient biopsies exhibited a significantly higher positive rate of β-catenin expression (72.86%) compared to paracancer normal tissues (19.44%) (p<0.01). β-Catenin expression was closely correlated with tumor differentiation, tumor size, serum α-fetoprotein (AFP) level and TACE treatment frequency (all p<0.05). Patients with negative β-catenin expression had longer PFS and OS after TACE compared to those with positive β-catenin expression (PFS: 44.2 vs. 14.1 months, p=0.004; OS: 56.4 vs. 35.9 months, p<0.001). Multivariate Cox regression analysis indicated that β-catenin expression in HCC patients treated with TACE was an independent prognostic factor for higher PFS and OS. The HCC patients with increased β-catenin expression have a poor prognosis with lower survival rate.